ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
Avatar

Molecular Milestones Using the BCR-ABL1 qPCR Level and Doubling Time After Imatinib Discontinuation to Predict Successful Treatment-free Remission: Treatment-free Remission Accomplished by Dasatinib (TRAD) Trial

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Dennis Kim
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Dennis Kim
0 views
November 23, 2018
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Scientific Session 7: Treatment-free Remission
12:56
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Molecular Milestones Using the BCR-ABL1 qPCR Level and Doubling Time…

Feat. D. Kim
18:28
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

What Prevents the Disease from Relapsing after TKI Discontinuation

Feat. S. Mustjoki
11:10
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

Treatment-free Remission in Patients with Chronic Phase Chronic Myel…

Feat. S. Saussele